1. Home
  2. ZEPP vs OMER Comparison

ZEPP vs OMER Comparison

Compare ZEPP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zepp Health Corporation

ZEPP

Zepp Health Corporation

HOLD

Current Price

$19.78

Market Cap

327.7M

Sector

Technology

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.93

Market Cap

894.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZEPP
OMER
Founded
2013
1994
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.7M
894.8M
IPO Year
2017
2008

Fundamental Metrics

Financial Performance
Metric
ZEPP
OMER
Price
$19.78
$11.93
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
116.4K
896.7K
Earning Date
01-01-0001
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
$887.39
N/A
Revenue Next Year
$26.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.13
$2.95
52 Week High
$61.50
$17.65

Technical Indicators

Market Signals
Indicator
ZEPP
OMER
Relative Strength Index (RSI) 40.77 52.45
Support Level $15.37 $11.09
Resistance Level $25.82 $12.57
Average True Range (ATR) 2.21 0.53
MACD -0.05 0.05
Stochastic Oscillator 15.52 65.52

Price Performance

Historical Comparison
ZEPP
OMER

About ZEPP Zepp Health Corporation

Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: